Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
Wave Life Sciences (NASDAQ:WVE), a clinical-stage biotechnology company specializing in RNA medicines, has scheduled its second quarter 2025 financial results conference call for July 30, 2025 at 8:30 a.m. ET. The company will present financial results and provide business updates during the webcast.
Investors and analysts can access the event through the company's investor relations website, with analysts having the option to participate in the Q&A session. An archived version of the webcast will be available after the live event.
Wave Life Sciences (NASDAQ:WVE), un'azienda biotecnologica in fase clinica specializzata in terapie a base di RNA, ha programmato la sua teleconferenza per la presentazione dei risultati finanziari del secondo trimestre 2025 per il 30 luglio 2025 alle 8:30 ET. Durante la diretta web, l'azienda presenterà i risultati finanziari e fornirà aggiornamenti sulle attività.
Investitori e analisti potranno seguire l'evento tramite il sito web dedicato agli investitori della società, con la possibilità per gli analisti di partecipare alla sessione di domande e risposte. Una registrazione della diretta sarà disponibile dopo l'evento.
Wave Life Sciences (NASDAQ:WVE), una empresa biotecnológica en etapa clínica especializada en medicamentos de ARN, ha programado su conferencia telefónica de resultados financieros del segundo trimestre de 2025 para el 30 de julio de 2025 a las 8:30 a.m. ET. La compañía presentará los resultados financieros y ofrecerá actualizaciones sobre el negocio durante la transmisión en línea.
Inversionistas y analistas podrán acceder al evento a través del sitio web de relaciones con inversionistas de la compañía, y los analistas tendrán la opción de participar en la sesión de preguntas y respuestas. Una versión archivada de la transmisión estará disponible después del evento en vivo.
Wave Life Sciences (NASDAQ:WVE)는 RNA 의약품을 전문으로 하는 임상 단계의 생명공학 회사로, 2025년 2분기 재무 실적 발표 컨퍼런스 콜을 2025년 7월 30일 오전 8시 30분(동부시간)에 예정하고 있습니다. 회사는 웹캐스트를 통해 재무 실적을 발표하고 사업 현황을 업데이트할 예정입니다.
투자자와 애널리스트는 회사의 투자자 관계 웹사이트를 통해 행사에 접속할 수 있으며, 애널리스트는 질의응답 세션에 참여할 수 있는 옵션이 제공됩니다. 생중계 종료 후 웹캐스트 녹화본도 제공될 예정입니다.
Wave Life Sciences (NASDAQ:WVE), une société biotechnologique en phase clinique spécialisée dans les médicaments à base d'ARN, a programmé sa conférence téléphonique sur les résultats financiers du deuxième trimestre 2025 pour le 30 juillet 2025 à 8h30 ET. La société présentera les résultats financiers et fournira des mises à jour commerciales lors du webinaire.
Les investisseurs et analystes pourront accéder à l'événement via le site web des relations investisseurs de la société, les analystes ayant la possibilité de participer à la session de questions-réponses. Une version archivée du webinaire sera disponible après l'événement en direct.
Wave Life Sciences (NASDAQ:WVE), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf RNA-Medikamente spezialisiert hat, hat seine Telefonkonferenz zur Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 30. Juli 2025 um 8:30 Uhr ET angesetzt. Das Unternehmen wird während des Webcasts die Finanzergebnisse präsentieren und Geschäftsaktualisierungen geben.
Investoren und Analysten können über die Investor-Relations-Website des Unternehmens an der Veranstaltung teilnehmen, wobei Analysten die Möglichkeit haben, an der Fragerunde teilzunehmen. Eine Aufzeichnung des Webcasts wird nach der Live-Veranstaltung verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, July 30, 2025, to review the company’s second quarter 2025 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
InvestorRelations@wavelifesci.com
Media:
MediaRelations@wavelifesci.com
FAQ
When is Wave Life Sciences (WVE) reporting Q2 2025 earnings?
How can investors access Wave Life Sciences Q2 2025 earnings call?
What will be discussed in Wave Life Sciences Q2 2025 earnings call?
Will there be a Q&A session during Wave Life Sciences earnings call?
